Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review

Recently, monoclonal antibodies (mAbs) directed against calcitonin gene-related peptide (CGRP) (Eptinezumab, Fremanezumab, and Galcanezumab) or its receptor (Erenumab) have been approved for clinical use as prophylactic drugs for high-frequency episodic and chronic migraine. While their therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Albanese, Maria, Mercuri, Nicola Biagio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911201/
https://www.ncbi.nlm.nih.gov/pubmed/35268319
http://dx.doi.org/10.3390/jcm11051228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911201/
https://www.ncbi.nlm.nih.gov/pubmed/35268319
http://dx.doi.org/10.3390/jcm11051228

Ejemplares similares